Wyeth Suggests Pristiq Could Surpass Effexor XR In Depression Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Combined global market for major depressive disorder and vasomotor symptoms represents 35 million women, firm says during Goldman Sachs investor conference.
You may also be interested in...
FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.
FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.
Noven Gains Phase III Vasomotor Symptoms Candidate With JDS Acquisition
Miami firm predicts four potential new product launches in four years based on specialty pharma JDS’ pipeline.